Get the Stockscreener App
712.20
1.15%
8.13
After Hours:
712.71
0.51
+0.07%
Argen X Se Adr stock is traded at $712.20, with a volume of 353.56K.
It is up +1.15% in the last 24 hours and up +18.94% over the past month.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
See More
Previous Close:
$704.07
Open:
$705.33
24h Volume:
353.56K
Relative Volume:
0.92
Market Cap:
$43.59B
Revenue:
$3.06B
Net Income/Loss:
$1.28B
P/E Ratio:
33.44
EPS:
21.2963
Net Cash Flow:
$447.35M
1W Performance:
+7.91%
1M Performance:
+18.94%
6M Performance:
+14.01%
1Y Performance:
+37.58%
1-Day Range:
$702.42
$716.62
1-Week Range:
$674.54
$716.62
52-Week Range:
$510.06
$716.62
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-08-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-13-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-17-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-12-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-17-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Nov-12-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-05-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Nov-01-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Strong Buy |
| Oct-04-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-06-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jul-25-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-31-23 | Initiated | Scotiabank | Sector Perform |
| Jul-24-23 | Downgrade | UBS | Buy → Neutral |
| Jul-17-23 | Resumed | Evercore ISI | Outperform |
| Jun-15-23 | Initiated | Societe Generale | Sell |
| May-31-23 | Initiated | UBS | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-07-22 | Initiated | William Blair | Outperform |
| Oct-12-22 | Initiated | Oppenheimer | Perform |
| Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-22 | Resumed | Stifel | Buy |
| May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-23-21 | Initiated | Deutsche Bank | Hold |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-18-21 | Initiated | UBS | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-23-21 | Initiated | Redburn | Neutral |
| Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
| Feb-10-20 | Initiated | BofA/Merrill | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-22-19 | Initiated | JP Morgan | Overweight |
| Sep-27-19 | Initiated | Wells Fargo | Market Perform |
| Sep-16-19 | Resumed | Cowen | Outperform |
| Jun-28-19 | Initiated | Robert W. Baird | Outperform |
| Jan-18-19 | Resumed | SunTrust | Buy |
| Jan-04-19 | Initiated | Morgan Stanley | Overweight |
| Dec-17-18 | Initiated | Goldman | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Jun-29-18 | Initiated | Nomura | Buy |
| Apr-09-18 | Initiated | SunTrust | Buy |
| Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded - Investor's Business Daily
Stocks With Rising Composite Ratings: argenx ADR - MSN
Argenx: study met primary endpoint - AInvest
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - GlobeNewswire Inc.
Argenx Shares Rise 0.42% with $190M Volume Ranking 464th Amid Biotech Sector Surge - AInvest
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Earnings call transcript: Argenx Q2 2025 reports robust earnings beat - Investing.com
Argenx's Growth Fuels Strong Demand for Vyvgart; Pipeline Continues to Develop - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - GlobeNewswire Inc.
This Stock Ran 31% In A Month. Will Upcoming News Revitalize It? - Investor's Business Daily
argenx ADR Earns Relative Strength Rating Upgrade; Hits Key Benchmark - inkl
Argenx NV ADR stock reaches all-time high at 689.13 USD By Investing.com - Investing.com South Africa
Argenx NV ADR stock reaches all-time high at 689.13 USD - Investing.com Nigeria
argenx ADR earnings beat by $3.26, revenue topped estimates - Investing.com South Africa
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Morgan Stanley assumes coverage on argenx stock with Overweight rating - Investing.com
Argenx stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Argenx stock falls after FDA flags serious risk signal with Vyvgart - Investing.com
argenx SE’s SWOT analysis: biotech stock’s growth potential and challenges - Investing.com
argenx ADR Shows Market Leadership With Jump To 84 RS Rating - Investor's Business Daily
10 Stocks Analysts Are Upgrading Today - Insider Monkey
Argenx Earnings: Vyvgart Delivers Strong Sales Growth; Prefilled Syringe Expands Patient Access - Morningstar
Metric Analysis: Argen X SE ADR (ARGX)’s Key Ratios in the Limelight - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
Biotech Tumbles. Why Its Sales Beat Wasn't Enough. - Investor's Business Daily
argenx ADR earnings beat by $0.34, revenue topped estimates - Investing.com Nigeria
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Argenx Stock Extends Rally In A Base As Earnings Loom - Investor's Business Daily
argenx ADR Earns Relative Strength Rating Upgrade - inkl
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating By Investing.com - Investing.com South Africa
Biotech Leader Surges On 'Best-Case Scenario' For Key Drug - Investor's Business Daily
Guggenheim maintains Buy on Argenx stock, target at $1,100 - Investing.com India
Guggenheim maintains Buy on Argenx stock, target at $1,100 By Investing.com - Investing.com South Africa
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating - Investing.com India
Stifel maintains $780 target on argenx stock after FDA nod - Investing.com
Stocks To Watch: argenx ADR Sees RS Rating Jump To 91 - Investor's Business Daily
Bernstein double upgrades Argenx to "outperform," raises price target to €755 By Investing.com - Investing.com South Africa
Bernstein double upgrades Argenx to "outperform," raises price target to €755 - Investing.com
Bernstein raises argenx stock rating, hikes target to EUR755 - Investing.com
TD Cowen maintains argenx stock with $761 target, bullish outlook - Investing.com India
TD Cowen maintains argenx stock with $761 target, bullish outlook By Investing.com - Investing.com South Africa
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.72%
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):